AstraZeneca PLC closed 20.36% short of its 52-week high of £133.88, which the company achieved on September 3rd.

This was the ADR's third consecutive day of losses.

AstraZeneca PLC has acquired a significant stake of 15.86% in Niox Group PLC, according to a recent company filing. This move ...

Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug ...

The deal with China’s CSPC Pharmaceuticals, focused on AI-driven research, aims to advance the discovery and development of ...

AstraZeneca has signed a research agreement worth more than $5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the ...

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

Friday’s deal with CSPC fits neatly within AstraZeneca’s business development strategy of upping investments in AI and in ...

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.

The pharmaceutical drug company AstraZeneca filed a lawsuit against the Utah attorney general claiming Utah's new law on ...

An AstraZeneca Plc affiliate suffered a greater than $180 million court loss Wednesday over its lackluster efforts to ...

AstraZeneca, a major pharmaceutical company, has sued Utah’s Attorney General Derek Brown over a recently passed state law ...